A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2015
At a glance
- Drugs Bococizumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Jul 2010 New trial record